Novo Nordisk Healthcare Ag

Novo Nordisk A/s

High Point Pharmaceuticals, LLC

Leo Laboratories Limited

Japan Tobacco Inc.

Leo-pharma A/s

Anders Klarskov Petersen

Peter Madsen

Preben H Olesen

Ole Hvilsted Olsen

Flemming E Nielsen

Lise Brown Christiansen

Xifu Liang

Michael Bech Jensen

Anne Marie Horneman

Andrew Neil Bowler

Takashi Inaba

Holger C Hansen

Soren Ebdrup

Claus Ulrich Jessen

Takashi Watanabe

Caspar Christensen

Steffen Kidal

Thomas Hogberg

Gunnar Grue-Sorensen

Rune Severinsen

Tsubasa Takeichi

Jan Bornholdt

Per Vedsoe

Kim Lebek Jensen

Hiromu Takiguchi

Akinobu Higashi

Henrik Valore

Palle Jakobsen

Svend Ludvigsen

Tina Moeller Tagmose

Niels Christian Kaarsholm

Tina Møller Tagmose

Helle Birk Olsen

Gunnar Grue-Sørensen

Henning Ralf Stennicke

Thomas Högberg

Dorte Bjerre Steensgaard

Soren Ostergaard

Jan Lindy Sørensen

Henrik Ostergaard

Jan Lindy Soerensen

Preben Houlberg Olesen

Flemming Elmelund Nielsen

Henrik ØStergaard

Jan Lindy SØRENSEN

Holger Claus Hansen

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof

The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II).  Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.

Method of producing ingenol-3-angelate

A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.

Method of acylating a peptide or protein

A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.

The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.

Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine

The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilizing agent (iii) comprising a &#x2014;C(&#x2550;N&#x2014;Z&#x2014;R)&#x2014;NH&#x2014;Z&#x2014;Rmotif, e.g. benzamidine compounds and guanidine compounds such as arginine.

Liquid, aqueous pharmaceutical compositions of factor VII polypeptides

The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a &#x2014;C(&#x2550;N&#x2014;Z&#x2014;R)&#x2014;NH&#x2014;Z&#x2014;Rmotif, e.g. benzamidine compounds and guanidine compounds such as arginine.

The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.

2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes

The present invention relates to novel compounds of formula [I], wherein Rrepresents heteroaryl, at least one substituent among R, Rand Rrepresent &#x2014;SR, &#x2014;S(O)Ror &#x2014;S(O)Rand the remaining substituents are as defined in the claims, that act as chemical uncouplers. Compounds of the invention are useful inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases associated therewith. 

Haloalkylsulfone substituted compounds useful for treating obesity and diabetes

2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes

The present invention relates to novel ligands for the HisZnsites of the R-state insulin hexamer having the formula A-B-C-D-X (III), wherein: A is a chemical group which reversibly binds to a HisZnsites of an insulin hexamer; B is a linker; C is a fragment consisting of 0 to 5 neutral amino acids; D is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and X is &#x2014;OH, &#x2014;NHor a diamino group. The present invention also relates to R-state insulin hexamers comprising such ligands, and aqueous insulin preparations comprising such R-state insulin hexamers.

[object Object]

The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilizing agent (iii) comprising a &#x2014;C(&#x2550;N-Z-R)&#x2014;NH-Z-Rmotif, e.g. benzamidine compounds and guanidine compounds such as arginine.

Growing community of inventors

Naerum, Denmark

Anders Klarskov Petersen